a Retrospective Study on the Systemic Treatment of LPP and FFA

CompletedOBSERVATIONAL
Enrollment

315

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Cicatricial AlopeciaLichen PlanopilarisLichen Plano-PilarisFrontal Fibrosing AlopeciaHair DiseasesScarring AlopeciaHair Loss/Baldness
Interventions
DRUG

Hydroxychloroquine

Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Methotrexate

This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Cyclosporine A

Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

DRUG

Retinoids

This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.

Trial Locations (1)

3015GD

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER